VITAL trial shows that 2000 IU/day of vitamin D3 significantly reduces telomere shortening, offering promising anti-aging and ...

PPARγ-targeting diabetes drug pioglitazone shows promise in reducing prostate cancer relapse risk, reveals new research.

Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of ...